Abstract 647P
Background
Colorectal cancer (CRC) results from the combination of genetic alterations and environmental risk factors. Several evidences indicate that the diet may have a role in prevention and progression of CRC, but more research is needed to clarify the heterogeneity of dietary associations with CRC.
Methods
Patient-derived xenografts (PDXs) were generated implanting subcutaneously human CRCs at different staging into immunodeficient mice, and feeding with control normal diet (ND) and classical western diet (WD). Tumor phenotype, transcriptomic, genetic and metabolomic were analyzed.
Results
The response to WD was heterogeneous among all generated PDXs. Only one out of three showed a greater growth in mice fed with WD. Particularly, WD induced transcriptomic perturbations of several genes related to epigenetic regulations and tumor progression, remodeling tumor microenvironment, promoting mucin secretion, mitochondria dysfunction and metabolic reprogramming. Interestingly, the three PDXs responded to the same WD with a distinct metabolomic profile that was validated through the machine learning. With whole exome sequencing, PDXs did not share the same somatic cancer mutations that could play a key role in conditioning response to a specific diet. Consistently, the same heterogeneous response to WD in tumor growth was observed in xenografts generated with CRC cell lines. To strictly mimics human diet, we tested in comparison to classic WD, humanized WD diet that displayed a different tumor behavior. The analysis of patient derived organoids developed from PDX fed with humanized diets revealed that the altered metabolic reprogramming acquired in vivo is also maintained in vitro in absence of any stimulus, suggesting a metabolic memory of cancer cells.
Conclusions
Specific CRC somatic mutations, modifying several signaling pathway and tumor metabolism promote tumor growth and progression, and could be predictive of a response to a specific diet. In this scenario, PDX could be considered as a suitable approach to study the response to the diet and to provide a screening of different diets in order to create a dietary guidance for CRC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Humanitas University.
Funding
PRIN.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11